376 476
[7]
Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415–22.[8]
Mazieres J, Fehrenbacher L, Rittmeyer A, et al. Non-classical re- sponse measured by immune-modified RECIST and post-progres- sion treatment effects of atezolizumab in 2L/3L NSCLC: results from the randomized phase II study POPLAR [abstract]. J Clin Oncol 2016;34(Suppl 15), abstr 9032.[9]
Dreicer R, Hoffman-Censits JH, Flaig TW, et al. Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC)Presented at: 52nd Annual American Society of Clinical On- cology (ASCO) Meeting; June 3–7, Chicago, IL. Abstract 4515; 2016.
[10] Opdivo (nivolumab) injection [prescribing information]. Princeton,
NJ: Bristol-Myers Squibb Co, updated November 23, 2015; 2015.
[11] Opdivo [summary of product characteristics]. Uxbridge, UK: Bris-
tol-Myers Squibb Pharma EEIG; 2015.
[12]
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13.
[13]
Raman R, Vaena D. Immunotherapy in metastatic renal cell carcino- ma: a comprehensive review. Biomed Res Int 2015;2015:367354.
[14]
Chiou VL, Burotto M. Pseudoprogression and immune-related re- sponse in solid tumors. J Clin Oncol 2015;33:3541–3.[15]
Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008;8:1.
[16]
George S, Motzer RJ, Hammers HJ, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2016;2:1179–86.
[17]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
[18]
Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007;10:285–93.
[19]
Leon L, Kosty M, Jahanzeb M, et al. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small- cell lung cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 2016;25:569–77.
[20]
Weinstock C, Maher VE, Zhang L, et al. FDA analysis of treatment beyond disease progression disease (PD) in patients with metastat- ic renal cell carcinoma (mRCC) treated with nivolumab vs. ever- olimus [abstract]. J Clin Oncol 2016;34(Suppl 15), abstr 4508.[21]
Mains JR, Donskov F, Pedersen EM, Madsen HH, Rasmussen F. Dynamic contrast-enhanced computed tomography-derived blood volume and blood flow correlate with patient outcome in meta- static renal cell carcinoma. Invest Radiol 2017;52:103–10.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 6 8 – 3 7 6
376